Enterovirus 71 Human
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Vaccine
2100%
+ 2 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Medigen Vaccine BiologicsTaiwan - Taipei
2 programsEV71 vaccineN/AVaccine1 trial
EV71 with adjuvant aluminium phosphatePHASE_21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Medigen Vaccine BiologicsEV71 with adjuvant aluminium phosphate
Medigen Vaccine BiologicsEV71 vaccine
Clinical Trials (2)
Total enrollment: 593 patients across 2 trials
A Clinical Study for Inactivated Vaccine Against EV71
Start: Sep 2014Est. completion: Aug 2017366 patients
Phase 2Completed
Long-Term Immunogenicity Study of Inactivated EV71 Vaccine in Children
Start: Aug 2019Est. completion: Dec 2021227 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Vaccine is the dominant modality (100% of programs)
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.